WO1994005296A3 - Emploi d'inhibiteurs de cytochrome p450 pour inhiber le metabolisme d'acridines a substitution azote - Google Patents

Emploi d'inhibiteurs de cytochrome p450 pour inhiber le metabolisme d'acridines a substitution azote Download PDF

Info

Publication number
WO1994005296A3
WO1994005296A3 PCT/US1993/008459 US9308459W WO9405296A3 WO 1994005296 A3 WO1994005296 A3 WO 1994005296A3 US 9308459 W US9308459 W US 9308459W WO 9405296 A3 WO9405296 A3 WO 9405296A3
Authority
WO
WIPO (PCT)
Prior art keywords
cytochrome
metabolism
inhibitors
inhibiting
nitrogen substituted
Prior art date
Application number
PCT/US1993/008459
Other languages
English (en)
Other versions
WO1994005296A2 (fr
Inventor
Thomas F Woolf
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/943,323 external-priority patent/US5422350A/en
Priority to SK264-95A priority Critical patent/SK26495A3/sk
Priority to KR1019950700943A priority patent/KR950703339A/ko
Priority to JP6507526A priority patent/JPH08501105A/ja
Priority to AU52905/93A priority patent/AU669586B2/en
Priority to AT93923110T priority patent/ATE212845T1/de
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Priority to DK93923110T priority patent/DK0659082T3/da
Priority to DE69331546T priority patent/DE69331546T2/de
Priority to EP93923110A priority patent/EP0659082B1/fr
Publication of WO1994005296A2 publication Critical patent/WO1994005296A2/fr
Publication of WO1994005296A3 publication Critical patent/WO1994005296A3/fr
Priority to FI951024A priority patent/FI951024A0/fi
Priority to NO950909A priority patent/NO307955B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Lubricants (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Procédé d'inhibition du métabolisme enzymatique d'acridines à substitution azote consistant à co-administrer avec l'acridine une dose efficace inhibant l'oxidase d'un inhibiteur de P450 1A2. L'activité de l'oxidase est induite par la bêta-naphtaflavone, le 3-méthylecholanthrène, l'Arochlore, la 2,3,7,8-tétrachlorodibenzo-p-dioxine et de l'isosafrol. L'inhibiteur d'oxidase peut être une naphthyridine, une xanthine, un phénoxy amino alcane, un imidazole de carbamoyle, une guanidine hétérocyclique, une quinoline ou un éther d'oxime de trifluorométhyle.
PCT/US1993/008459 1992-09-10 1993-09-08 Emploi d'inhibiteurs de cytochrome p450 pour inhiber le metabolisme d'acridines a substitution azote WO1994005296A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP93923110A EP0659082B1 (fr) 1992-09-10 1993-09-08 Emploi d'inhibiteurs de cytochrome p450 pour inhiber le metabolisme d'acridines a substitution azote
KR1019950700943A KR950703339A (ko) 1992-09-10 1993-09-08 질소 치환된 아크리딘의 대사를 억제하기 위한 시토크롬 P450 억제제의 용도(Use of Cytochrome P450 Inhibitors for Inhibiting he Metabolism of Nitrogen Substituted Acridine)
JP6507526A JPH08501105A (ja) 1992-09-10 1993-09-08 窒素置換されたアクリジンおよびチトクロームｐ４５０阻害剤および使用方法
AU52905/93A AU669586B2 (en) 1992-09-10 1993-09-08 Use of cytochrome P450 inhibitors for inhibiting the metabolism of nitrogen substituted acridines
AT93923110T ATE212845T1 (de) 1992-09-10 1993-09-08 Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
SK264-95A SK26495A3 (en) 1992-09-10 1993-09-08 N-substituted acridines and inhibitors of cytochrome p450 and methods of their use
DK93923110T DK0659082T3 (da) 1992-09-10 1993-09-08 Anvendelse af cytochrom P450 inhibitorer til inhibering af metabolismen af nitrogensubstituerede acridiner
DE69331546T DE69331546T2 (de) 1992-09-10 1993-09-08 Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
FI951024A FI951024A0 (fi) 1992-09-10 1995-03-06 Typpi-substituoidut akridiinit ja sytokromi P450-inhibiittorit ja käyttömenetelmät
NO950909A NO307955B1 (no) 1992-09-10 1995-03-09 Blandinger omfattende nitrogensubstituert acridin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/943,323 US5422350A (en) 1992-09-10 1992-09-10 Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
US07/943,323 1992-09-10
US08/100,917 1993-08-09
US08/100,917 US5466696A (en) 1992-09-10 1993-08-09 Tacrine and cytochrome P450 oxidase inhibitors and methods of use

Publications (2)

Publication Number Publication Date
WO1994005296A2 WO1994005296A2 (fr) 1994-03-17
WO1994005296A3 true WO1994005296A3 (fr) 1994-04-28

Family

ID=26797688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/008459 WO1994005296A2 (fr) 1992-09-10 1993-09-08 Emploi d'inhibiteurs de cytochrome p450 pour inhiber le metabolisme d'acridines a substitution azote

Country Status (18)

Country Link
US (1) US5466696A (fr)
EP (1) EP0659082B1 (fr)
JP (1) JPH08501105A (fr)
KR (1) KR950703339A (fr)
AT (1) ATE212845T1 (fr)
AU (1) AU669586B2 (fr)
CA (1) CA2141425A1 (fr)
CZ (1) CZ48095A3 (fr)
DE (1) DE69331546T2 (fr)
DK (1) DK0659082T3 (fr)
ES (1) ES2171419T3 (fr)
FI (1) FI951024A0 (fr)
HU (1) HU217845B (fr)
NO (1) NO307955B1 (fr)
NZ (1) NZ256940A (fr)
PT (1) PT659082E (fr)
SK (1) SK26495A3 (fr)
WO (1) WO1994005296A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
JPH11507356A (ja) * 1995-06-07 1999-06-29 アブマックス，インコーポレイティド 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU779900B2 (en) * 1999-07-22 2005-02-17 Organogenesis Inc. In vivo induction for enhanced function of isolated hepatocytes
EP1465979A4 (fr) * 2001-12-21 2007-11-14 Organogenesis Inc Chambre a volume adaptable pour culture cellulaire et assistance d'organe
US20040092427A1 (en) * 2002-09-25 2004-05-13 Anil Gulati Method and composition for treating alzheimer's disease and dementias of vascular origin
US7583551B2 (en) 2004-03-10 2009-09-01 Micron Technology, Inc. Power management control and controlling memory refresh operations
DE102005044815A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung
WO2008153722A1 (fr) * 2007-05-22 2008-12-18 The Board Of Regents Of The University Of Texas System Régulation post-translationnelle d'activités catalytiques du cytochrome p450 46a1, et utilisations associées

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2233970A (en) * 1941-03-04 Quinoline compound and process of
DE1643240A1 (de) * 1966-09-16 1971-06-24 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer racemischer oder optisch aktiver 1-Phenoxy-2-aminoalkane
GB1338169A (en) * 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
SU429813A1 (ru) * 1971-08-20 1974-05-30 Способ лечения туберкулеза легких
AR223983A1 (es) * 1978-08-25 1981-10-15 Dainippon Pharmaceutical Co Un procedimiento para-preparar derivados de acido 6-halogeno-4-oxo-7-(1-piperazinil)-1,8-naftiridin-3-carboxilico
SU789112A1 (ru) * 1979-04-12 1980-12-23 Научно-исследовательский институт экспериментальной и клинической медицины Способ лечени экстрасистолической аритмии у детей
SU827081A1 (ru) * 1979-06-05 1981-05-07 Донецкий Медицинский Институт Им.M.Горького Способ лечени вазомоторных головныхбОлЕй
GB2091249A (en) * 1980-12-23 1982-07-28 Fordonal Sa Xanthine derivatives
SU1049065A1 (ru) * 1981-01-09 1983-10-23 Andronova Liliya Z Способ лечени заикани
JPS57134482A (en) * 1981-02-13 1982-08-19 Dainippon Pharmaceut Co Ltd 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8- naphthyridine-3-carboxylic acid-3/2 hydrate and its preparation
SU1156700A1 (ru) * 1982-01-19 1985-05-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ лечени неврозов
SU1210789A1 (ru) * 1983-07-21 1986-02-15 Военно-Медицинская Ордена Ленина Краснознаменная Академия Им.С.М.Кирова Способ диагностики функционального нарушени желудочной секреции
SU1196002A1 (ru) * 1984-06-28 1985-12-07 Запорожский государственный институт усовершенствования врачей им.М.Горького Способ лечени хронического сальпингоофорита
US4835275A (en) * 1984-10-25 1989-05-30 Hoechst-Roussel Pharmaceuticals, Inc. Method of preparing 9-amino-1,2,3,4,-tetrahydroacridin-1-ones and related compounds
US4631286A (en) * 1984-10-25 1986-12-23 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
ATE63903T1 (de) * 1984-10-25 1991-06-15 Hoechst Roussel Pharma 9-amino-1,2,3,4-tetrahydroacridin-1-ol und verwandte verbindungen, verfahren zu ihrer herstellung und verwendung als arzneimittel.
US4695573A (en) * 1984-10-25 1987-09-22 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4754050A (en) * 1984-10-25 1988-06-28 Hoechst-Roussel Pharmaceuticals, Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
SU1537252A1 (ru) * 1985-03-28 1990-01-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ лечени парестезий полости рта
SU1416125A1 (ru) * 1986-02-21 1988-08-15 Одесский Научно-Исследовательский Институт Курортологии Способ лечени заболеваний суставов
SU1389050A1 (ru) * 1986-07-28 1990-08-30 Niiex Meditsiny An Sssr Cпocoб лeчehия aлkoгoлизma
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
WO1989002739A1 (fr) * 1987-10-05 1989-04-06 Pfizer Inc. Derives de 4-aminopyridine
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
EP0369388B1 (fr) * 1988-11-16 1993-05-19 Hoechst-Roussel Pharmaceuticals Incorporated Hydroxy-1,2,3,4-tétrahydroaminoacridines, procédé pour leur préparation et leur utilisation comme médicaments
GB8827704D0 (en) * 1988-11-28 1988-12-29 Fujisawa Pharmaceutical Co New acridine derivatives & processes for their production
US4999430A (en) * 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J.W. PAXTON: "The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbit-", CANCER CHEMOTHER. PHARMACOL., vol. 18, no. 3, 1986, pages 208 - 212 *
P. DOGTEROM: "Hepatotoxicity of tetrahydroaminoacridine in isolated rat hepatocytes: effect of glutathione and vitamin E.", BIOCHEM. PHARMACOL., vol. 37, no. 12, 1988, pages 2311 - 2313, XP025514268, DOI: doi:10.1016/0006-2952(88)90356-5 *
S. MADDEN: "An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro.", BIOCHEM. PHARMACOL., vol. 46, no. 1, July 1993 (1993-07-01), pages 13 - 20, XP025567640, DOI: doi:10.1016/0006-2952(93)90342-T *
S. MADDEN: "An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine: in vitro studies with human liver microsomes.", BR. J. CLIN. PHARMACOL., vol. 36, no. 2, August 1993 (1993-08-01), pages 145P *

Also Published As

Publication number Publication date
NO307955B1 (no) 2000-06-26
JPH08501105A (ja) 1996-02-06
NO950909D0 (no) 1995-03-09
DE69331546T2 (de) 2002-10-31
ATE212845T1 (de) 2002-02-15
HU9500704D0 (en) 1995-04-28
HU217845B (hu) 2000-04-28
CZ48095A3 (en) 1995-12-13
EP0659082A1 (fr) 1995-06-28
NZ256940A (en) 1996-03-26
HUT70979A (en) 1995-11-28
SK26495A3 (en) 1996-05-08
DK0659082T3 (da) 2002-06-17
EP0659082B1 (fr) 2002-02-06
CA2141425A1 (fr) 1994-03-17
AU5290593A (en) 1994-03-29
FI951024A (fi) 1995-03-06
US5466696A (en) 1995-11-14
NO950909L (no) 1995-03-09
FI951024A0 (fi) 1995-03-06
WO1994005296A2 (fr) 1994-03-17
ES2171419T3 (es) 2002-09-16
PT659082E (pt) 2002-07-31
KR950703339A (ko) 1995-09-20
AU669586B2 (en) 1996-06-13
DE69331546D1 (de) 2002-03-21

Similar Documents

Publication Publication Date Title
AU8155894A (en) Methods of inhibiting thrombin
AU7578894A (en) Methods for inhibiting smooth muscle cell proliferation and restinosis
CA2071629A1 (fr) Utilisation de substances sensibilisantes a l&#39;insuline pour le traitement de l&#39;hypertension
BG101937A (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors
PL310474A1 (en) Application of rilusole in treating neuro-aids diseases
WO1994005296A3 (fr) Emploi d&#39;inhibiteurs de cytochrome p450 pour inhiber le metabolisme d&#39;acridines a substitution azote
AU8154794A (en) Methods of inhibiting seborrhea and acne
MY112973A (en) Methods for inhibiting vascular smooth muscle cell migration
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
MY106333A (en) Adenosine derivatives,their production and use.
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
AU6129096A (en) Use of pyrrolidine derivatives in the treatment of alcoholism
AU8155094A (en) Methods of inhibiting hirsutism and alopecia in women
ZA982808B (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
AU7921698A (en) Use of phospholamban inhibitors for increasing coronary flow
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis
MD980248A (ro) Derivaţi ai carbolinei
MX9803271A (es) Uso de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,6-tetrahid ropiridina para la preparacion de farmacos para el tratamiento de esclerosis lateral aminotrofica.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CZ FI HU JP KR NO NZ PT RU SK UA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CZ FI HU JP KR NO NZ PT RU SK UA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2141425

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 256940

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV1995-480

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1993923110

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 26495

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 951024

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1993923110

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1995-480

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1993923110

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1995-480

Country of ref document: CZ